FAP-targeting CAR-T cells have shown promising anti-tumour responses, enhancing the activity of CD8+ T cells, which deplete tumour stroma and reduce vascular density, both of which promote tumour progression and metastasis (70). This evidence concerns the gene CD8A and neoplasm.